pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,047 catalysts · 4,728 grant · 3,940 device 510k · 3,100 approval · 3,080 8k filing · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 51 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: recall×type: approval×from 2025-01-21×clear all
type
  • grant4,728
  • device 510k3,940
  • approval3,100
  • 8k filing3,080
  • device pma2,000
  • device recall2,000
device adverse event
1,000
  • recall947
  • earnings583
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of Jan 20, 2025

    41
    ›Jan 21, 2025approval568d agoPOTELIGEO (MOGAMULIZUMAB-KPKC) — FDA approvalmogamulizumab

    Sponsor: KYOWA KIRIN. Form: INJECTABLE. Route: INJECTION

    full page →mogamulizumab →fda approvals ↗
    ›Jan 21, 2025approval568d agoEPYSQLI (ECULIZUMAB-AAGH) — FDA approvalEPYSQLI

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTION. Route: SOLUTION

    full page →EPYSQLI →fda approvals ↗
    ›Jan 21, 2025approval568d agoADDYI (FLIBANSERIN) — FDA approvalSprout2 Inc

    Sponsor: SPROUT PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 22, 2025approval567d agoHALOPERIDOL — FDA approvalHALOPERIDOL

    Sponsor: AIPING PHARM INC. Form: TABLET. Route: ORAL

    full page →HALOPERIDOL →fda approvals ↗
    ›Jan 22, 2025approval567d agoFINGOLIMOD HYDROCHLORIDE — FDA approvalFINGOLIMOD HYDROCHLORIDE

    Sponsor: AUROBINDO PHARMA LTD. Form: CAPSULE. Route: ORAL

    full page →FINGOLIMOD HYDROCHLORIDE →fda approvals ↗
    ›Jan 22, 2025approval567d agoZYPREXA ZYDIS (OLANZAPINE) — FDA approvalDR REDDYS LABORATORIES LTD

    Sponsor: CHEPLAPHARM. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL

    full page →fda approvals ↗
    ›Jan 22, 2025approval567d agoZYPREXA RELPREVV (OLANZAPINE PAMOATE) — FDA approvalCHEPLAPHARM Arzneimittel GmbH

    Sponsor: CHEPLAPHARM. Form: SUSPENSION, EXTENDED RELEASE. Route: INTRAMUSCULAR

    full page →fda approvals ↗
    ›Jan 22, 2025approval567d agoZYPREXA (OLANZAPINE) — FDA approvalTEVA PHARMACEUTICAL INDUSTRIES LTD

    Sponsor: CHEPLAPHARM. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jan 22, 2025approval567d agoZYPREXA (OLANZAPINE) — FDA approvalTEVA PHARMACEUTICAL INDUSTRIES LTD

    Sponsor: CHEPLAPHARM. Form: POWDER. Route: INTRAMUSCULAR

    full page →fda approvals ↗
    ›Jan 22, 2025approval567d agoLYBALVI (OLANZAPINE) — FDA approval(olanzapine + samidorphan l-malate)

    Sponsor: ALKERMES INC. Form: TABLET. Route: ORAL

    full page →(olanzapine + samidorphan l-malate) →fda approvals ↗
    ›Jan 22, 2025approval567d agoABILIFY MAINTENA KIT (ARIPIPRAZOLE) — FDA approvalaripiprazole LA

    Sponsor: OTSUKA PHARM CO LTD. Form: FOR SUSPENSION, EXTENDED RELEASE. Route: INTRAMUSCULAR

    full page →aripiprazole LA →fda approvals ↗
    ›Jan 22, 2025approval567d agoRYKINDO (RISPERIDONE) — FDA approvalDelpor Inc

    Sponsor: SHANDONG LUYE. Form: FOR SUSPENSION, EXTENDED RELEASE. Route: INTRAMUSCULAR

    full page →fda approvals ↗
    ›Jan 22, 2025approval567d agoFINGOLIMOD HYDROCHLORIDE — FDA approvalFINGOLIMOD HYDROCHLORIDE

    Sponsor: GLENMARK PHARMS LTD. Form: CAPSULE. Route: ORAL

    full page →FINGOLIMOD HYDROCHLORIDE →fda approvals ↗
    ›Jan 22, 2025approval567d agoFINGOLIMOD HYDROCHLORIDE — FDA approvalFINGOLIMOD HYDROCHLORIDE

    Sponsor: GLENMARK PHARMS LTD. Form: CAPSULE. Route: ORAL

    full page →FINGOLIMOD HYDROCHLORIDE →fda approvals ↗
    ›Jan 22, 2025approval567d agoXTANDI (ENZALUTAMIDE) — FDA approvalenzalutamide

    Sponsor: ASTELLAS. Form: TABLET. Route: ORAL

    full page →enzalutamide →fda approvals ↗
    ›Jan 22, 2025approval567d agoXTANDI (ENZALUTAMIDE) — FDA approvalenzalutamide

    Sponsor: ASTELLAS. Form: CAPSULE. Route: ORAL

    full page →enzalutamide →fda approvals ↗
    ›Jan 22, 2025approval567d agoHALDOL (HALOPERIDOL DECANOATE) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jan 22, 2025approval567d agoUZEDY (RISPERIDONE) — FDA approvalDelpor Inc

    Sponsor: TEVA. Form: SUSPENSION, EXTENDED RELEASE. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Jan 22, 2025recall567d agoAmerisource Health Services LLC recall (Cls II)Greenstone LLC

    glipiZIDE, Extended-Release Tablets, 2.5 mg, 30-count (3x10 blister cards) carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC: 60687-480-21, Unit Dose NDC: 60687-480-11 — Reason: Failed Dissolution Specifications: — Status: Terminated

    full page →fda recalls ↗
    ›Jan 22, 2025recall567d agoAkron Pharma, Inc. recall (Cls III)aTYR PHARMA INC

    Acetaminophen, 325 mg Tablets, 100 Tablets per bottle, Akron Pharma, Manufactured for: Akron Pharma Inc., Fairfield, NJ 07034, NDC 71399-8014-01. — Reason: Labeling: Not Elsewhere Classified: Tablets/Capsules imprinted with wrong ID. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 22, 2025recall567d agoAmerisource Health Services LLC recall (Cls II)Taro Pharmaceutical Laboratories Inc (Inactive)

    Clobazam Tablets, 10 mg, packaged in 30 tablets per carton (3x10 blister cards each), Rx Only, Amneal Pharmaceuticals LLC, Distributed by: American Health Packaging, Columbus, Ohio 43217, NDC 60687-423-11 — Reason: Presence of Foreign Tablets/Capsules — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 22, 2025recall567d agoAkron Pharma, Inc. recall (Cls III)aTYR PHARMA INC

    Diphenhydramine HCl 25 mg, 1000 Capsules per bottle, Akron Pharma, Manufactured for: Akron Pharma, Inc., 373 RT US 46 W Building E., Suite 117, Fairfield, NJ 07004, NDC 71399-8028-2. — Reason: Labeling: Not Elsewhere Classified: Tablets/Capsules imprinted with wrong ID. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 22, 2025recall567d agoAkron Pharma, Inc. recall (Cls III)aTYR PHARMA INC

    Diphenhydramine HCl 50 mg, 1000 capsules per bottle, Akron Pharma, Manufactured for: Akron Pharma, Inc. 373 Route US 46, Building E, Suite 117, Fairfield, NJ 07004, NDC 71399-8026-02. — Reason: Labeling: Not Elsewhere Classified: Tablets/Capsules imprinted with wrong ID. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 22, 2025recall567d agoAlcon Research LLC recall (Cls I)Alcon Laboratories Inc

    Systane Lubricant Eye Drops, Ultra PF, Sterile, 25 Vials (0.7mL Each), Manufactured for: Alcon Laboratories, Inc. Forth Worth, TX 76134 — Reason: Non-Sterility — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 22, 2025recall567d agoAkron Pharma, Inc. recall (Cls III)aTYR PHARMA INC

    Acetaminophen Regular Strength, 325 mg, 100 Tablets per bottle, Akron Pharma, Inc., 373 RT US 46 W Building E, Suite 117, Fairfield, NJ 07004, NDC 71399-8024-01 . — Reason: Labeling: Not Elsewhere Classified: Tablets/Capsules imprinted with wrong ID. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 22, 2025recall567d agoViatris Inc recall (Cls II)Viatris Inc

    Cardura XL (doxazosin) extended release tablets 8 mg, 30-count bottle, Rx only, Distributed by Viatris Specialty LLC, Morgantown, WV 26505, NDC 58151-079-93 — Reason: Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing. — Status: Terminated

    full page →fda recalls ↗
    ›Jan 22, 2025recall567d agoAkron Pharma, Inc. recall (Cls III)aTYR PHARMA INC

    Diphenhydramine HCl 25 mg, 100 capsules per bottle, Akron Pharma, Manufactured for: Akron Pharma, Inc., 373 RT US 46 W Building E, Suite 117, Fairfield, NJ 07004, NDC 71399-8028-1. — Reason: Labeling: Not Elsewhere Classified: Tablets/Capsules imprinted with wrong ID. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 22, 2025recall567d agoAkron Pharma, Inc. recall (Cls III)aTYR PHARMA INC

    Acetaminophen Extra Strength 500 mg, 100 Tablets per bottle, Akron Pharma, Inc., 373 RT US 46 W Building E, Suite 117, Fairfield, NJ 07004, NDC 71399-8022-01. — Reason: Labeling: Not Elsewhere Classified: Tablets/Capsules imprinted with wrong ID. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 22, 2025recall567d agoViatris Inc recall (Cls II)Viatris Inc

    Cardura XL (doxazosin) extended release tablets 4 mg, 30 -count bottle, Rx only, Distributed by Viatris Specialty LLC, Morgantown, WV 26505, NDC 58151-078-93 — Reason: Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing. — Status: Terminated

    full page →fda recalls ↗
    ›Jan 22, 2025recall567d agoAkron Pharma, Inc. recall (Cls III)aTYR PHARMA INC

    Acetaminophen Extra Strength 500 mg, 1000 Tablets per bottle, Akron Pharma, Manufactured for: Akron Pharma Inc., 373 US RT 46 W Building E, Suite 117, Fairfield, NJ 07034, NDC 71399-8022-02 — Reason: Labeling: Not Elsewhere Classified: Tablets/Capsules imprinted with wrong ID. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 23, 2025approval566d agoBOSENTAN — FDA approvalBOSENTAN

    Sponsor: WATSON LABS INC. Form: TABLET. Route: ORAL

    full page →BOSENTAN →fda approvals ↗
    ›Jan 23, 2025approval566d agoBOSENTAN — FDA approvalBOSENTAN

    Sponsor: WATSON LABS INC. Form: TABLET. Route: ORAL

    full page →BOSENTAN →fda approvals ↗
    ›Jan 23, 2025approval566d agoDEPAKOTE (DIVALPROEX SODIUM) — FDA approvaldivalproex sodium DR

    Sponsor: ABBVIE. Form: CAPSULE, DELAYED REL PELLETS. Route: ORAL

    full page →divalproex sodium DR →fda approvals ↗
    ›Jan 23, 2025approval566d agoDEPAKOTE ER (DIVALPROEX SODIUM) — FDA approvaldivalproex sodium DR

    Sponsor: ABBVIE. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →divalproex sodium DR →fda approvals ↗
    ›Jan 23, 2025approval566d agoDEPAKOTE (DIVALPROEX SODIUM) — FDA approvaldivalproex sodium DR

    Sponsor: ABBVIE. Form: TABLET, DELAYED RELEASE. Route: ORAL

    full page →divalproex sodium DR →fda approvals ↗
    ›Jan 23, 2025approval566d agoLISDEXAMFETAMINE DIMESYLATE — FDA approvalLISDEXAMFETAMINE DIMESYLATE

    Sponsor: ASCENT PHARMS INC. Form: CAPSULE. Route: ORAL

    full page →LISDEXAMFETAMINE DIMESYLATE →fda approvals ↗
    ›Jan 24, 2025approval565d agoMEKINIST (TRAMETINIB) — FDA approvalSpexotras

    Sponsor: NOVARTIS. Form: SOLUTION. Route: ORAL

    full page →Spexotras →fda approvals ↗
    ›Jan 24, 2025approval565d agoMEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalSpexotras

    Sponsor: NOVARTIS. Form: TABLET. Route: ORAL

    full page →Spexotras →fda approvals ↗
    ›Jan 24, 2025approval565d agoLEQEMBI (LECANEMAB-IRMB) — FDA approvallecanemab

    Sponsor: EISAI INC. Form: INJECTABLE. Route: INJECTION

    full page →lecanemab →fda approvals ↗
    ›Jan 24, 2025approval565d agoAVTOZMA (TOCILIZUMAB-ANOH) — FDA approvalAVTOZMA

    Sponsor: CELLTRION INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →AVTOZMA →fda approvals ↗
    ›Jan 26, 2025approval563d agoNIZORAL ANTI-DANDRUFF (KETOCONAZOLE) — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: KRAMER. Form: SHAMPOO. Route: TOPICAL

    full page →fda approvals ↗

    Week of Jan 27, 2025

    9
    ›Jan 27, 2025approval562d agoCARBAMAZEPINE — FDA approvalcarbamazepine ER

    Sponsor: TORRENT PHARMS. Form: TABLET, CHEWABLE. Route: ORAL

    full page →carbamazepine ER →fda approvals ↗
    ›Jan 27, 2025approval
    ← prev
    page 1 of 81
    next →
    562d ago
    CARBAMAZEPINE — FDA approvalcarbamazepine ER

    Sponsor: TORRENT PHARMS. Form: TABLET. Route: ORAL

    full page →carbamazepine ER →fda approvals ↗
    ›Jan 27, 2025approval562d agoCARBAMAZEPINE — FDA approvalcarbamazepine ER

    Sponsor: TORRENT PHARMS. Form: TABLET. Route: ORAL

    full page →carbamazepine ER →fda approvals ↗
    ›Jan 27, 2025approval562d agoENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approvaltrastuzumab deruxtecan

    Sponsor: DAIICHI SANKYO. Form: INJECTABLE. Route: INJECTION

    full page →trastuzumab deruxtecan →fda approvals ↗
    ›Jan 27, 2025approval562d agoENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approvaltrastuzumab deruxtecan

    Sponsor: DAIICHI SANKYO. Form: INJECTABLE. Route: INJECTION

    full page →trastuzumab deruxtecan →fda approvals ↗
    ›Jan 28, 2025approval561d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Jan 28, 2025approval561d agoEPYSQLI (ECULIZUMAB-AAGH) — FDA approvalEPYSQLI

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTION. Route: SOLUTION

    full page →EPYSQLI →fda approvals ↗
    ›Jan 28, 2025approval561d agoOZEMPIC (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Jan 29, 2025approval560d agoOLANZAPINE AND FLUOXETINE HYDROCHLORIDE (FLUOXETINE HYDROCHLORIDE) — FDA approvalEpic Pharma LLC

    Sponsor: TEVA PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    $TEVA36.14+2.21%
    $ATYR
    $TEVA36.14+2.21%
    $ATYR
    $RDY12.15-0.57%
    $VTRS16.28-0.91%
    $ALKS49.40+0.47%
    $ATYR
    $ATYR
    $ATYR
    $ATYR
    $VTRS16.28-0.91%
    $ABBV247.97+0.78%
    $ATYR
    $ABBV247.97+0.78%
    $ABBV247.97+0.78%
    $NVS156.79+0.29%
    $NVS156.79+0.29%